GSK Bolsters Vaccine Business With $3.3 Billion Deal for Affinivax
wsj.com
news
2022-05-31 11:14:00

The deal for Affinivax is GSK's largest in vaccines since its acquisition of Novartis' vaccine business in 2015.Photo: Chris Ratcliffe/Bloomberg NewsListen to article(2 minutes)GSK PLC agreed to pay up to $3.3 billion to acquire vaccine maker Affinivax Inc., in a deal that would hand the British pharmaceutical giant a new vaccine technology targeting common bacterial diseases such as meningitis and pneumonia.The British pharmaceutical company, formerly known as GlaxoSmithKline, said it would pay $2.
